Innovation in aging · 2026
Variation in Medicare Part D and Part B drug spending among older adults with Alzheimer's disease and related dementias.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Jang Seyeon, Chen Jie
Аннотация
BACKGROUND AND OBJECTIVES: This study examined Medicare Part D and Part B drug spending and beneficiary out-of-pocket (OOP) costs among community-dwelling Medicare fee-for-service (FFS) beneficiaries with Alzheimer's disease and related dementias (ADRD), assessing variation by dual eligibility, state, and Accountable Care Organization (ACO) enrollment.
RESEARCH DESIGN AND METHODS: We conducted a cross-sectional analysis using the 2022 Medicare Beneficiary Summary File linked to the Cost and Use file. The sample included 1 372 696 community-dwelling Medicare FFS beneficiaries with ADRD, including 575 308 beneficiaries with five or more chronic conditions. Outcomes included annual Medicare payments and beneficiary OOP costs for Parts D and B drugs. Analyses were stratified by dual eligibility duration, state, and ACO enrollment, with adjusted estimates from generalized linear models.
RESULTS: Medicare Part D drug spending was substantial, increasing with dual-eligibility duration: $8732-$9107 among beneficiaries with full-year dual eligibility and exceeding $11 500 among those with 5+ chronic conditions. Beneficiary OOP costs were highest among Medicare-only beneficiaries and markedly lower among dually eligible individuals. Medicare Part B drug spending was highest among Medicare-only beneficiaries and varied widely by state, ranging from $433 to $1827 among Medicare-only beneficiaries and from $179 to $1446 among dually eligible beneficiaries. After adjustment, differences in Parts D and B drug spending by ACO enrollment were modest.
DISCUSSION AND IMPLICATIONS: Parts D and B drug costs among Medicare beneficiaries with ADRD vary by dual eligibility and geography. Limited associations with ACO enrollment underscore the need for better medication management integration in value-based care for high-need older adults with ADRD.
RESEARCH DESIGN AND METHODS: We conducted a cross-sectional analysis using the 2022 Medicare Beneficiary Summary File linked to the Cost and Use file. The sample included 1 372 696 community-dwelling Medicare FFS beneficiaries with ADRD, including 575 308 beneficiaries with five or more chronic conditions. Outcomes included annual Medicare payments and beneficiary OOP costs for Parts D and B drugs. Analyses were stratified by dual eligibility duration, state, and ACO enrollment, with adjusted estimates from generalized linear models.
RESULTS: Medicare Part D drug spending was substantial, increasing with dual-eligibility duration: $8732-$9107 among beneficiaries with full-year dual eligibility and exceeding $11 500 among those with 5+ chronic conditions. Beneficiary OOP costs were highest among Medicare-only beneficiaries and markedly lower among dually eligible individuals. Medicare Part B drug spending was highest among Medicare-only beneficiaries and varied widely by state, ranging from $433 to $1827 among Medicare-only beneficiaries and from $179 to $1446 among dually eligible beneficiaries. After adjustment, differences in Parts D and B drug spending by ACO enrollment were modest.
DISCUSSION AND IMPLICATIONS: Parts D and B drug costs among Medicare beneficiaries with ADRD vary by dual eligibility and geography. Limited associations with ACO enrollment underscore the need for better medication management integration in value-based care for high-need older adults with ADRD.